Gene of the month: BRAFGOVENDER, Dhirendra; CHETTY, Runjan.Journal of clinical pathology. 2012, Vol 65, Num 11, pp 986-988, issn 0021-9746, 3 p.Article

Molecular Pathways: BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative PhosphorylationHAQ, Rizwan; FISHER, David E; WIDLUND, Hans R et al.Clinical cancer research (Print). 2014, Vol 20, Num 9, pp 2257-2263, issn 1078-0432, 7 p.Article

Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutationsKINNO, T; TSUTA, K; KUSHIMA, R et al.Annals of oncology. 2014, Vol 25, Num 1, pp 138-142, issn 0923-7534, 5 p.Article

BRAF in Melanoma: Current Strategies and Future DirectionsSALAMA, April K. S; FLAHERTY, Keith T.Clinical cancer research (Print). 2013, Vol 19, Num 16, pp 4326-4334, issn 1078-0432, 9 p.Article

BRAF mutations in aberrant crypt foci and hyperplastic polyposisBEACH, Robyn; ON-ON CHAN, Annie; WU, Tsung-Teh et al.The American journal of pathology. 2005, Vol 166, Num 4, pp 1069-1075, issn 0002-9440, 7 p.Article

Molecular Pathways: Response and Resistance to BRAF and MEK Inhibitors in BRAF^V600E TumorsMEGHNA DAS THAKUR; STUART, Darrin D.Clinical cancer research (Print). 2014, Vol 20, Num 5, pp 1074-1080, issn 1078-0432, 7 p.Article

BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK InhibitionHUTCHINSON, Katherine E; LIPSON, Doron; PUZANOV, Igor et al.Clinical cancer research (Print). 2013, Vol 19, Num 24, pp 6696-6702, issn 1078-0432, 7 p.Article

BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: The Iitalian Melanoma Intergroup StudyCASULA, Milena; COLOMBINO, Maria; LISSIA, Amelia et al.Journal of clinical oncology. 2004, Vol 22, Num 2, pp 286-292, issn 0732-183X, 7 p.Article

Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)FALCHOOK, Gerald S; LONG, Georgina V; CHIN, Melvin T et al.Clinical cancer research (Print). 2014, Vol 20, Num 17, pp 4449-4458, issn 1078-0432, 10 p.Article

BRAF Inactivation Drives Aneuploidy by Deregulating CRAFKAMATA, Tamihiro; HUSSAIN, Jahan; GIBLETT, Susan et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 21, pp 8475-8486, issn 0008-5472, 12 p.Article

Sprouty2 Association with B-Raf Is Regulated by Phosphorylation and Kinase ConformationBRADY, Suzanne C; COLEMAN, Mathew L; MUNRO, June et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 17, pp 6773-6781, issn 0008-5472, 9 p.Article

Role of BRAF in Thyroid OncogenesisCARONIA, Lisa M; PHAY, John E; SHAH, Manisha H et al.Clinical cancer research (Print). 2011, Vol 17, Num 24, pp 7511-7517, issn 1078-0432, 7 p.Article

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway ActivationFEI SU; BRADLEY, William D; LEE, Richard J et al.Cancer research (Chicago, Ill.). 2012, Vol 72, Num 4, pp 969-978, issn 0008-5472, 10 p.Article

Oncogenic BRAF is required for tumor growth and maintenance in melanoma modelsHOEFLICH, Klaus P; GRAY, Daniel C; MURRAY, Lesley J et al.Cancer research (Baltimore). 2006, Vol 66, Num 2, pp 999-1006, issn 0008-5472, 8 p.Article

Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAFEMUSS, Victoria; GARNETT, Mathew; MASON, Clive et al.Cancer research (Baltimore). 2005, Vol 65, Num 21, pp 9719-9726, issn 0008-5472, 8 p.Article

Absence of BRAF gene mutations differentiates Spitz nevi from malignant melanomaMIHIC-PROBST, Daniela; PERREN, Aurel; SCHMID, Sonja et al.Anticancer research. 2004, Vol 24, Num 4, pp 2415-2418, issn 0250-7005, 4 p.Article

The T1799A point mutation is present in posterior uveal melanomaJANSSEN, C. S; SIBBETT, R; HENRIQUEZ, F. L et al.British journal of cancer. 2008, Vol 99, Num 10, pp 1673-1677, issn 0007-0920, 5 p.Article

BRAF mutation in solid cell nest hyperplasia associated with papillary thyroid carcinoma. A precursor Lesion?CAMESELLE-TEIJEIRO, José; ABDULKADER, Ihab; PEREZ-BECERRA, Raquel et al.Human pathology. 2009, Vol 40, Num 7, pp 1029-1035, issn 0046-8177, 7 p.Article

MAPK pathway activation through BRAF gene fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with diagnostic, prognostic, and therapeutic potentialJEUKEN, Judith W. M; WESSELING, Pieter.Journal of pathology (Print). 2010, Vol 222, Num 4, pp 324-328, issn 0022-3417, 5 p.Article

Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and ChallengesHU-LIESKOVAN, Siwen; ROBERT, Lidia; MORENO, Blanca Homet et al.Journal of clinical oncology. 2014, Vol 32, Num 21, pp 2248-2254, issn 0732-183X, 7 p.Article

Dabrafenib: First Global ApprovalBALLANTYNE, Anita D; GARNOCK-JONES, Karly P.Drugs (Basel). 2013, Vol 73, Num 12, pp 1367-1376, issn 0012-6667, 10 p.Article

Association of galectin-3 expression with melanoma progression and prognosisBROWN, Ewan R; DOIG, Tamasin; ANDERSON, Niall et al.European journal of cancer (1990). 2012, Vol 48, Num 6, pp 865-874, issn 0959-8049, 10 p.Article

BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell ImmunotherapyKOYA, Richard C; MOK, Stephen; RIBAS, Antoni et al.Cancer research (Chicago, Ill.). 2012, Vol 72, Num 16, pp 3928-3937, issn 0008-5472, 10 p.Article

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsFLAHERTY, Keith T; INFANTE, Jeffery R; KUDCHADKAR, Ragini et al.The New England journal of medicine. 2012, Vol 367, Num 18, pp 1694-1703, issn 0028-4793, 10 p.Article

Recent advances in the understanding of Langerhans cell histiocytosisBADALIAN-VERY, Gayane; VERGILIO, Jo-Anne; DEGAR, Barbara A et al.British journal of haematology. 2012, Vol 156, Num 2, pp 163-172, issn 0007-1048, 10 p.Article